Compare KRMD & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | VERU |
|---|---|---|
| Founded | 1980 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 39.8M |
| IPO Year | N/A | 1990 |
| Metric | KRMD | VERU |
|---|---|---|
| Price | $5.79 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.88 | ★ $25.00 |
| AVG Volume (30 Days) | 184.9K | ★ 193.6K |
| Earning Date | 11-12-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | N/A |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $2.11 |
| 52 Week High | $6.61 | $14.20 |
| Indicator | KRMD | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 35.09 |
| Support Level | $5.55 | $2.23 |
| Resistance Level | $6.61 | $2.42 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 29.97 | 8.21 |
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.